Move to topTop
May 23, 2012

Terumo Corporation (TOKYO: 4543, TSE Section 1) announced today that from this July it will begin a European sales launch of its "LUNAWAVE®" OFDI system, an intravascular diagnostic imaging system that applies optical frequency, as well as its "FastView®" OFDI imaging catheter. Terumo aims to achieve the revenue of 0.3 billion yen in fiscal year 2012. And, it further aims for 3.5 billion yen in fiscal year 2014 by adding the sales in Japan.

OFDI (Optical Frequency Domain Imaging) employs light applied to the inside of blood vessels from the tip of a catheter, and constructs an intravascular cross-sectional image through a new technology that analyzes the reflection from the vessel walls. It is mainly utilized in coronary intervention to verify the conditions inside blood vessels and confirm the stent apposition. OFDI achieves high image resolution, and is highly expected in its ability to display differences in the tissue characterization of vascular walls, which has been difficult to detect in the past.

Terumo's "LUNAWAVE" OFDI intravascular imaging system was used in live demonstration cases performed at EuroPCR 2012 (May 15-18th), the world's leading cardiovascular intervention course, drawing a considerable amount of interest among numerous physicians.

"The quality of OFDI imaging system was amazing, and it was surpassed conventional diagnostic imaging technologies. I highly expect the system to contribute to providing even safer and more effective coronary interventions", commented Dr. Bernard Chevalier (Clinique Jacques Cartier, France), the physician who used the system in the live demonstration cases.

025.jpg

Terumo will provide a broad lineup of intervention technologies, including not only treatment devices such as drug-eluting stent but also diagnostic imaging system, with the goal to contribute to the safety and reliability of coronary intervention.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.